CD8A and neoplasm: Treatment of cancer cells resulted in reduced tumor growth and metastasis in mouse models.23–26 The use of P-SiaFNAc has also revealed how sialoglycans influence antigen-presenting cell interactions with CD8+ T cells which may enable potentiating anti-tumor immune responses.27,28 We have recently developed more potent analogues of P-SiaFNAc by taking advantage of the substrate tolerance of the sialoglycan biosynthesis enzymes for C-5 substitutions of sialic acid,.29–31 We found that C-5 carbamate derivatives of P-SiaFNAc, e.g. P-SiaFNEtoc have about 30-times enhanced inhibitory potency.